• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有人类患者代谢、组织学和转录组学特征的饮食诱导非酒精性脂肪性肝炎基因小鼠模型的纵向特征分析。

Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients.

作者信息

Abe Naomichi, Kato Sayuka, Tsuchida Takuma, Sugimoto Kanami, Saito Ryuta, Verschuren Lars, Kleemann Robert, Oka Kozo

机构信息

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda-shi, Saitama 335-8505, Japan

Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda-shi, Saitama 335-8505, Japan.

出版信息

Biol Open. 2019 May 1;8(5):bio041251. doi: 10.1242/bio.041251.

DOI:10.1242/bio.041251
PMID:31023717
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6550083/
Abstract

Non-alcoholic steatohepatitis (NASH) is a fast-growing liver disease in the Western world. Currently, only a few animal models show both the metabolic and histological features of human NASH. We aimed to explore murine NASH models in a time dependent manner that exhibit metabolic, histological and transcriptomic hallmarks of human NASH. For this, the murine strains C57BL/6J, ob/ob, and KK-A were used and three types of nutritional regimes were administered: normal chow diet (NCD); high-fat, high-fructose, and high-cholesterol diet (fast food diet; FFD); or choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD), for 2, 4, 8, 12, 18, 24, and 30 weeks. All strains under the FFD and CDAHFD regimes developed steatohepatitis. Among the strains treated with FFD, the non-alcoholic fatty liver disease (NAFLD) activity score, fibrosis progression and metabolic abnormalities such as hyperinsulinemia and obesity were more pronounced in ob/ob mice than in C57BL/6J and KK-A mice. In ob/ob mice fed FFD, the development of hepatic crown-like structures was confirmed. Furthermore, molecular pathways involved in steatohepatitis and fibrosis showed significant changes from as early as 2 weeks of starting the FFD regime. Ob/ob mice fed FFD showed metabolic, histological, and transcriptomic dysfunctions similar to human NASH, suggesting their potential as an experimental model to discover novel drugs for NASH.

摘要

非酒精性脂肪性肝炎(NASH)在西方世界是一种快速发展的肝脏疾病。目前,只有少数动物模型同时具备人类NASH的代谢和组织学特征。我们旨在以时间依赖性方式探索表现出人类NASH代谢、组织学和转录组学特征的小鼠NASH模型。为此,使用了小鼠品系C57BL/6J、ob/ob和KK-A,并给予三种营养方案:正常饲料饮食(NCD);高脂肪、高果糖和高胆固醇饮食(快餐饮食;FFD);或胆碱缺乏、L-氨基酸限定的高脂肪饮食(CDAHFD),持续2、4、8、12、18、24和30周。在FFD和CDAHFD方案下的所有品系都发展出了脂肪性肝炎。在接受FFD治疗的品系中,ob/ob小鼠的非酒精性脂肪性肝病(NAFLD)活动评分、纤维化进展以及高胰岛素血症和肥胖等代谢异常比C57BL/6J和KK-A小鼠更为明显。在喂食FFD的ob/ob小鼠中,证实了肝冠样结构的形成。此外,早在开始FFD方案的2周起,参与脂肪性肝炎和纤维化的分子途径就显示出显著变化。喂食FFD的ob/ob小鼠表现出与人类NASH相似的代谢、组织学和转录组功能障碍,表明它们作为发现NASH新药的实验模型的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/17306b598406/biolopen-8-041251-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/e174fee69732/biolopen-8-041251-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/0771339a4541/biolopen-8-041251-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/165cc0395f14/biolopen-8-041251-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/de9781e9a7f3/biolopen-8-041251-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/f32792ad7340/biolopen-8-041251-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/17306b598406/biolopen-8-041251-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/e174fee69732/biolopen-8-041251-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/0771339a4541/biolopen-8-041251-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/165cc0395f14/biolopen-8-041251-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/de9781e9a7f3/biolopen-8-041251-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/f32792ad7340/biolopen-8-041251-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd4c/6550083/17306b598406/biolopen-8-041251-g6.jpg

相似文献

1
Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients.具有人类患者代谢、组织学和转录组学特征的饮食诱导非酒精性脂肪性肝炎基因小鼠模型的纵向特征分析。
Biol Open. 2019 May 1;8(5):bio041251. doi: 10.1242/bio.041251.
2
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.朝着标准化饮食诱导和活检确认的非酒精性脂肪性肝炎小鼠模型迈进:饮食脂肪源的影响。
World J Gastroenterol. 2019 Sep 7;25(33):4904-4920. doi: 10.3748/wjg.v25.i33.4904.
3
Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.通过肝活检追踪非酒精性脂肪性肝炎疾病的肥胖饮食诱导小鼠模型。
World J Hepatol. 2016 Jun 8;8(16):673-84. doi: 10.4254/wjh.v8.i16.673.
4
Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.在喂食胆碱缺乏、L-氨基酸限定的高脂肪饮食的小鼠模型中的肝细胞癌。
Int J Exp Pathol. 2017 Aug;98(4):221-233. doi: 10.1111/iep.12240. Epub 2017 Sep 12.
5
INT-767 improves histopathological features in a diet-induced mouse model of biopsy-confirmed non-alcoholic steatohepatitis.INT-767 改善了经活检证实的非酒精性脂肪性肝炎小鼠模型中的组织病理学特征。
World J Gastroenterol. 2018 Jan 14;24(2):195-210. doi: 10.3748/wjg.v24.i2.195.
6
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.利拉鲁肽、奥贝胆酸和 Elafibranor 在经活检证实的非酒精性脂肪性肝炎肥胖小鼠模型中的代谢和肝脏作用。
World J Gastroenterol. 2018 Jan 14;24(2):179-194. doi: 10.3748/wjg.v24.i2.179.
7
Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease.磺基转移酶 2 基因敲除可减轻非酒精性脂肪性肝病小鼠模型的脂肪性肝炎和肝纤维化。
Am J Physiol Gastrointest Liver Physiol. 2020 Sep 1;319(3):G333-G344. doi: 10.1152/ajpgi.00150.2019. Epub 2020 Jul 20.
8
The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.FATZO小鼠是2型糖尿病的下一代模型,在喂食添加了果糖的西式饮食时会发展为非酒精性脂肪性肝病(NAFLD)和非酒精性脂肪性肝炎(NASH)。
BMC Gastroenterol. 2019 Mar 18;19(1):41. doi: 10.1186/s12876-019-0958-4.
9
Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.在小鼠的高脂肪-高胆固醇-高糖饮食模型中,非酒精性脂肪变性进展为脂肪性肝炎和肝纤维化与促进炎症和肝肿瘤的危险信号的累积平行。
J Transl Med. 2015 Jun 16;13:193. doi: 10.1186/s12967-015-0552-7.
10
Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by F-FPP-RGD PET.通过F-FPP-RGD PET评估非酒精性脂肪性肝炎(NASH)模型小鼠肝脏整合素αvβ3的表达
EJNMMI Res. 2018 May 31;8(1):40. doi: 10.1186/s13550-018-0394-4.

引用本文的文献

1
Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General Population.TLM3生物标志物组合对普通人群中MAFLD早期纤维化发展的预后价值
Liver Int. 2025 Jul;45(7):e70169. doi: 10.1111/liv.70169.
2
Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice Mimic the Key Transcriptomic Signatures Observed in Humans.西式饮食诱导的非酒精性脂肪肝疾病小鼠模拟了人类观察到的关键转录组特征。
Physiol Res. 2024 Aug 31;73(4):593-608. doi: 10.33549/physiolres.935237.
3
Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease.

本文引用的文献

1
Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr-/-.Leiden Mice.奥贝胆酸调节人类非酒精性脂肪性肝炎特征性的血清代谢物和基因特征,并减轻Ldlr-/-。莱顿小鼠的炎症和纤维化进展。
Hepatol Commun. 2018 Oct 29;2(12):1513-1532. doi: 10.1002/hep4.1270. eCollection 2018 Dec.
2
Key Inflammatory Processes in Human NASH Are Reflected in Ldlr.Leiden Mice: A Translational Gene Profiling Study.人类非酒精性脂肪性肝炎中的关键炎症过程在载脂蛋白E基因缺陷(Ldlr).Leiden小鼠中得到体现:一项转化基因谱研究。
Front Physiol. 2018 Feb 23;9:132. doi: 10.3389/fphys.2018.00132. eCollection 2018.
3
六个月高脂肪饮食和果糖-葡萄糖饮料联合应用于非酒精性脂肪肝疾病小鼠模型的部分验证。
Endocrine. 2024 Aug;85(2):704-716. doi: 10.1007/s12020-024-03769-5. Epub 2024 Mar 20.
4
Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).新型口服 SPT 抑制剂 CH5169356 抑制非酒精性脂肪性肝炎(NASH)小鼠模型中肝星状细胞的激活并改善肝纤维化。
Pharmacol Res Perspect. 2023 Jun;11(3):e01094. doi: 10.1002/prp2.1094.
5
Development of a reference and proficiency chemical list for human steatosis endpoints .开发人类脂肪变性终点的参考和能力化学物质清单。
Front Endocrinol (Lausanne). 2023 Apr 24;14:1126880. doi: 10.3389/fendo.2023.1126880. eCollection 2023.
6
Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research.遗传和饮食诱导的非酒精性脂肪性肝病(NAFLD)动物模型研究。
Int J Mol Sci. 2022 Dec 13;23(24):15791. doi: 10.3390/ijms232415791.
7
Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies.非酒精性脂肪性肝病(NAFLD)的小鼠模型:发病机制和药物治疗。
Int J Biol Sci. 2022 Sep 6;18(15):5681-5697. doi: 10.7150/ijbs.65044. eCollection 2022.
8
Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver.通过阻断肝脏中的线粒体融合来预防和逆转巨型线粒体和脂肪变性
iScience. 2022 Feb 26;25(4):103996. doi: 10.1016/j.isci.2022.103996. eCollection 2022 Apr 15.
9
Heat-Inactivated Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr-/-.Leiden Mice.热灭活可改善肠道通透性,但不能预防饮食诱导肥胖 LDLR-/-. Leiden 小鼠非酒精性脂肪性肝炎的发生。
Int J Mol Sci. 2022 Feb 19;23(4):2325. doi: 10.3390/ijms23042325.
10
Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression.小鼠中前胶原C蛋白酶增强因子-1(PCPE-1)缺乏可减轻肝纤维化,但不影响非酒精性脂肪性肝炎的进展。
PLoS One. 2022 Feb 11;17(2):e0263828. doi: 10.1371/journal.pone.0263828. eCollection 2022.
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
果糖和糖:非酒精性脂肪性肝病的主要介质。
J Hepatol. 2018 May;68(5):1063-1075. doi: 10.1016/j.jhep.2018.01.019. Epub 2018 Feb 2.
4
Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.在一个转化性非酒精性脂肪性肝炎(NASH)小鼠模型中揭示与NASH相关纤维化发病的预测性分子特征。
Cell Mol Gastroenterol Hepatol. 2017 Oct 14;5(1):83-98.e10. doi: 10.1016/j.jcmgh.2017.10.001. eCollection 2018.
5
Preclinical models of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的临床前模型。
J Hepatol. 2018 Feb;68(2):230-237. doi: 10.1016/j.jhep.2017.10.031. Epub 2017 Nov 9.
6
A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.一项对纤维化非酒精性脂肪性肝炎小鼠模型进行的全身、组织和细胞生理学纵向研究,该模型高度逼真地模拟了人类病情。
Am J Physiol Gastrointest Liver Physiol. 2017 Jun 1;312(6):G666-G680. doi: 10.1152/ajpgi.00213.2016. Epub 2017 Feb 23.
7
Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.通过肝活检追踪非酒精性脂肪性肝炎疾病的肥胖饮食诱导小鼠模型。
World J Hepatol. 2016 Jun 8;8(16):673-84. doi: 10.4254/wjh.v8.i16.673.
8
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.全球非酒精性脂肪性肝病流行病学——患病率、发病率和结局的荟萃分析评估。
Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
9
Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies.体重指数与非酒精性脂肪性肝病风险:两项电子健康记录前瞻性研究
J Clin Endocrinol Metab. 2016 Mar;101(3):945-52. doi: 10.1210/jc.2015-3444. Epub 2015 Dec 16.
10
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.非酒精性脂肪性肝炎:可用治疗选择有限,但有前景的药物正在研发中,且在监管审批途径方面取得了近期进展。
Drugs. 2015 Aug;75(12):1373-92. doi: 10.1007/s40265-015-0437-3.